The global presbyopia market is projected to grow at a CAGR of 4.9% during the forecast period from 2026 to 2036, supported by the rising aging population, increasing prevalence of age-related near vision impairment, greater disease awareness, and improved diagnosis rates. The expanding pipeline of pharmacological therapies and medical devices is also expected to create new opportunities in the presbyopia treatment landscape.

Emerging therapies and devices, including Phentolamine (Opus Genetics/Viatris), MicroLine (Pilocarpine Ophthalmic) (Eyenovia), GLK-302 (Glaukos Corporation), CorVision (Intrastromal Corneal Inlay) (LinkoCare Life Sciences AB), and the riboflavin/UV-A medical device (RegenSight), are being evaluated for their potential to address unmet needs in presbyopia management.

According to DelveInsight's recently published Presbyopia Market Insights report, the study provides a comprehensive assessment of current treatment practices, marketed and emerging therapies, market shares, epidemiology, and historical and forecasted market sizes from 2022 to 2036 across the seven major markets, including the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Presbyopia Market Key Highlights

  • The presbyopia market in the seven major markets was valued at approximately USD 11 billion in 2025.
  • The United States accounted for approximately 50% of the total presbyopia treatment market in 2025, representing the largest share among the seven major markets.
  • The total number of prevalent presbyopia cases across the seven major markets was estimated at nearly 290,000 cases in 2025 and is projected to increase during the forecast period.
  • Leading companies involved in the presbyopia treatment landscape include Opus Genetics, Viatris, Eyenovia, Glaukos Corporation, LinkoCare Life Sciences AB, RegenSight, AbbVie, Orasis Pharmaceuticals, LENZ Therapeutics, and Tenpoint Therapeutics, among others.
  • Key emerging therapies and devices include Phentolamine, MicroLine, GLK-302, CorVision, and the riboflavin/UV-A medical device.
  • MicroLine (Eyenovia) is an emerging topical presbyopia treatment candidate that is projected in the report to potentially receive approval in the United States by 2027.

Discover more about the Presbyopia Market:
https://www.delveinsight.com/report-store/presbyopia-market?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Key Factors Driving the Presbyopia Market

Rising Presbyopia Prevalence

In 2025, the United States accounted for approximately 125,000 diagnosed prevalent cases of presbyopia. The diagnosed patient population is expected to increase during the forecast period, supported by population growth, improvements in diagnostic practices, and greater awareness of age-related vision impairment.

Growing Aging Population

The increasing global population of adults aged 40 years and older is a major contributor to the growth of the presbyopia market. As the eye's natural lens gradually loses flexibility with age, the ability to focus on nearby objects declines, increasing the demand for vision correction and treatment options.

Technological Advancements in Vision Correction

Advancements in multifocal lenses, laser-assisted procedures, corneal inlays, and presbyopia-correcting intraocular lenses are expanding the available treatment options. These innovations aim to improve visual outcomes, treatment precision, and patient satisfaction.

Expansion of Emerging Therapies and Devices

The presbyopia market is expected to evolve with the development of novel pharmacological therapies and medical devices. Key candidates include Phentolamine, MicroLine, GLK-302, CorVision, and the riboflavin/UV-A medical device, among others.

Presbyopia Market Analysis

Presbyopia management includes corrective eyewear, contact lenses, prescription eye drops, and surgical interventions. Treatment selection depends on the severity of near-vision impairment, patient preferences, and clinical considerations.

Commonly used surgical approaches include:

  • Conductive Keratoplasty
  • LASIK
  • LASEK
  • Photorefractive Keratectomy (PRK)
  • Lens-based procedures and presbyopia-correcting intraocular lenses

The United States currently represents the largest market among the seven major markets and has several approved pharmacological treatment options, including VUITY, QLOSI, VIZZ, and YUVEZZI, according to the supplied market analysis.

The report also highlights the continued development of therapies with novel mechanisms of action. However, the late-stage presbyopia pipeline remains relatively limited, with candidates such as Phentolamine and MicroLine identified as potential future contributors to market growth.

Learn more about the Presbyopia Treatment Market:
https://www.delveinsight.com/report-store/presbyopia-market?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Presbyopia Competitive Landscape

The presbyopia competitive landscape includes pharmaceutical companies, biotechnology firms, and medical device developers working to improve near-vision correction and address limitations associated with existing treatment approaches.

Key emerging therapies and devices include:

  • Phentolamine Ophthalmic Solution 0.75%: Opus Genetics/Viatris
  • MicroLine (Pilocarpine Ophthalmic): Eyenovia
  • GLK-302: Glaukos Corporation
  • CorVision (Intrastromal Corneal Inlay): LinkoCare Life Sciences AB
  • Riboflavin/UV-A Medical Device: RegenSight

Phentolamine Ophthalmic Solution 0.75%

Phentolamine Ophthalmic Solution 0.75% is an investigational treatment being developed for presbyopia. It is designed to act as a non-selective alpha-adrenergic antagonist and aims to improve near vision through changes in pupil size without directly affecting the ciliary muscle.

According to the supplied market information, the candidate was under regulatory assessment following the submission of a supplemental New Drug Application in early 2026. The company anticipated a regulatory decision by the end of 2026.

CorVision

CorVision, developed by LinkoCare Life Sciences AB, is a bioengineered corneal microlens designed for presbyopia correction. The collagen-based device is intended for implantation into a corneal pocket and aims to provide an alternative approach to near-vision correction.

The development of pharmacological therapies and medical devices such as Phentolamine and CorVision may contribute to the evolution of the presbyopia treatment landscape, subject to clinical outcomes and regulatory decisions.

Explore the Presbyopia Competitive Landscape:
https://www.delveinsight.com/report-store/presbyopia-market?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Recent Developments in the Presbyopia Market

  • January 2026: Tenpoint Therapeutics announced that it had secured USD 235 million through the closing of a Series B preferred stock financing and a credit facility. The funding is intended to support the commercialization of YUVEZZI.
  • September 2025: LENZ Therapeutics announced the availability of VIZZ (aceclidine ophthalmic solution) 1.44% in the United States. The company also announced the initiation of professional product sample distribution to optometrists and ophthalmologists.
  • July 2025: The US Food and Drug Administration approved VIZZ (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia in adults, according to the supplied market information.

What Is Presbyopia?

Presbyopia is an age-related vision condition in which the eye gradually loses its ability to focus on nearby objects. It commonly develops after the age of 40 as the natural lens becomes less flexible.

Individuals with presbyopia may experience blurred near vision, eye strain, headaches, and difficulty reading or performing close-up tasks. The condition can be managed through reading glasses, bifocals, contact lenses, prescription eye drops, and surgical treatment options.

Presbyopia Epidemiology Segmentation

The Presbyopia Market Insights report provides an assessment of the historical and forecasted patient population across the seven major markets for the period 2022–2036.

In 2025, the United States accounted for the highest number of diagnosed prevalent presbyopia cases among the seven major markets, with approximately 125,000 cases.

The epidemiology analysis includes:

  • Total prevalent cases of presbyopia
  • Total diagnosed cases of presbyopia
  • Age-specific cases of presbyopia
  • Gender-specific cases of presbyopia
  • Severity-specific cases of presbyopia
  • Total treated cases of presbyopia

Explore the Presbyopia Market Report:
https://www.delveinsight.com/report-store/presbyopia-market?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Presbyopia Market Report Metrics

  • Study Period: 2022–2036
  • Coverage: 7MM
  • Presbyopia Market Size in 2025: USD 11 billion
  • Key Companies: Opus Genetics, Viatris, Eyenovia, Glaukos Corporation, LinkoCare Life Sciences AB, RegenSight, AbbVie, Orasis Pharmaceuticals, LENZ Therapeutics, Tenpoint Therapeutics, and others.
  • Key Therapies and Devices: Phentolamine, MicroLine, GLK-302, CorVision, riboflavin/UV-A medical device, VUITY, QLOSI, VIZZ, YUVEZZI, and others.

Scope of the Presbyopia Market Report

The report provides a comprehensive assessment of the presbyopia market, covering:

  • Therapeutic Assessment: Analysis of marketed and emerging presbyopia therapies.
  • Market Dynamics: Assessment of market drivers, barriers, and emerging treatment opportunities.
  • Competitive Intelligence: Evaluation of the competitive landscape, SWOT analysis, and market-entry strategies.
  • Unmet Needs and Expert Insights: Assessment of unmet needs, key opinion leader perspectives, analyst views, market access, and reimbursement.
  • Market Forecast: Historical and forecasted market sizes across the seven major markets.

Discover more about the Presbyopia Clinical Pipeline:
https://www.delveinsight.com/report-store/presbyopia-market?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Table of Contents

  1. Presbyopia Market Key Insights
  2. Presbyopia Market Report Introduction
  3. Executive Summary
  4. Key Events
  5. Epidemiology and Market Forecast Methodology
  6. Presbyopia Market Overview at a Glance
  7. Presbyopia: Overview
  8. Guidelines of Presbyopia
  9. Regulation of Medical Devices
  10. Epidemiology and Patient Population
  11. Patient Journey
  12. Marketed Presbyopia Drugs
  13. Emerging Presbyopia Drugs
  14. Marketed Presbyopia Medical Devices
  15. Emerging Presbyopia Medical Devices
  16. Presbyopia Market: Seven Major Market Analysis
  17. Presbyopia Market Unmet Needs
  18. Presbyopia Market SWOT Analysis
  19. Key Opinion Leader Views on Presbyopia
  20. Presbyopia Market Access and Reimbursement
  21. Bibliography

Related Reports

Presbyopia Clinical Trial Analysis Pipeline

Presbyopia Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key presbyopia companies, including Orasis Pharmaceuticals, Novartis, Cellix Bio, Visus Therapeutics, AbbVie, Vyluma, Lenz Therapeutics, Ocuphire Pharma, JIXING Pharmaceuticals, Eyenovia, and others.

Myopia Market

Myopia Market Insight, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key myopia companies such as Vyluma, Inc., Sydnexis, Inc., Ocumension Limited, Santen Pharmaceutical, Cloudbreak Therapeutics, Nevakar, Inc., Eyenovia, Stuart Therapeutics, Cellix Bio, JeniVision, Zhaoke Ophthalmology, and others.

About DelveInsight

DelveInsight is a leading business consulting and market research firm focused exclusively on the life sciences industry. The company provides comprehensive market research, consulting, and competitive intelligence solutions to support pharmaceutical, biotechnology, and healthcare organizations in making informed business decisions.

Through its subscription-based platform, PharmDelve, DelveInsight provides access to healthcare and pharmaceutical market research reports.

Contact Us

Kanishk

[email protected]